Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Protective effect of carvedilol on adriamycin-induced left ventricular dysfunction in children with acute lymphoblastic leukemia
Journal of Cardiac Failure, Volume 18, No. 8, Year 2012
Notification
URL copied to clipboard!
Description
Background: Adriamycin (ADR) is a potent chemotherapeutic agent widely used in the treatment of childhood acute lymphoblastic leukemia (ALL); its clinical use is limited owing to its marked cardiotoxicity. The present study investigated the possible protective role of carvedilol on ADR-induced left ventricular dysfunction in children with ALL. Methods and Results: Fifty children with newly diagnosed ALL were included in this study. They were divided into 2 equal groups: 1) ADR; and 2) ADR + carvedilol. Patients were evaluated with conventional 2-dimensional echocardiographic examination (2D), pulsed tissue Doppler (PTD), and 2-dimensional longitudinal strain echocardiography (2DS) before and after therapy. Plasma lactic dehydrogenase (LDH), creatine phosphokinase (CPK), and troponin I levels were also determined before and after therapy. ADR treatment reduced left ventricular systolic dysfunction as assessed by a significant decrease in fractional shortening (FS) (2D) and global peak-systolic strain (GPSS; 2DS). In addition, ADR treatment significantly increased plasma troponin I and LDH. Pretreatment of ADR-treated patients with carvedilol resulted in a significant increase in FS (2D) and GPSS (2DS). Furthermore, carvedilol pretreatment inhibited ADR-induced increase in plasma troponin I and LDH. Conclusions: These results suggested a protective role of carvedilol against ADR-induced cardiotoxicity. © 2012 Elsevier Inc. All rights reserved.
Authors & Co-Authors
El-Shitany, Nagla Abd Aziz
Egypt, Tanta
Tanta University
Saudi Arabia, Jeddah
King Abdulaziz University
Tolba, Osama A.
Egypt, Tanta
Faculty of Medicine
El-Shanshory, Mohammed Ramadan
Egypt, Tanta
Faculty of Medicine
Elhawary, Eslam E.
Egypt, Tanta
Faculty of Medicine
Statistics
Citations: 96
Authors: 4
Affiliations: 3
Identifiers
Doi:
10.1016/j.cardfail.2012.06.416
ISSN:
10719164
e-ISSN:
15328414
Research Areas
Maternal And Child Health
Study Design
Cohort Study